Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
NCT ID: NCT00779922
Last Updated: 2016-10-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
39 participants
INTERVENTIONAL
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM and impaired renal function at completion of 3 cycles of treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
NCT01270932
Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression
NCT04872023
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00772915
A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma
NCT00915408
Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients
NCT03001804
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1 to 5
lenalidomide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lenalidomide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years at the time of signing the informed consent form
* Stable renal function
Exclusion Criteria
* Any prior use of Revlimid ®
* Any contraindication to Revlimid ® and especially:
* Lack of acceptable method of birth control for female of childbearing potential (FCPB)
* Men who don't agree to use condom during the study and 4 weeks after the last study drug intake if their partner is a FCPB.
* Pregnant or breast feeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Poitiers University Hospital
Poitiers, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REVIR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.